February 3, 2012
By:Formulary staff
Hospitals and healthcare facilities should require all employees to get an annual flu shot, a group representing many of the nation?s largest employers emphasized again at a press conference Wednesday in Washington, DC.
 |
January 26, 2012
By:From staff reports
Indian drug giant Ranbaxy has accepted a consent decree filed by the U.S. Department of Justice on behalf of FDA. The decree, which must still be accepted by the U.S. District Court for the District of Maryland, requires Ranbaxy to fix long-standing manufacturing problems at plants in India as well as a plant in the United States.
|
December 22, 2011
By:From staff reports
FDA announced that it is evaluating the case of a patient with multiple sclerosis who died 24 hours following administration of the first dose of fingolimod (Gilenya).
|
January 1, 2012
By:Mari Edlin
New molecular entities (NMEs) for calendar year 2011 number 30, considerably above the average of 23 during the past 10 years. Notably among this list are 8 drugs for cancer; 10 targeting orphan diseases; 2 each for hepatitis C and chronic obstructive pulmonary disease (COPD); and 3 anticoagulants.
|
January 1, 2012
By:Kate M. O'Dell, PharmD, BCPS
Constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation affect millions of Americans. Use of agents currently available for treatment is not supported by well-controlled clinical studies. A new drug application for linaclotide, an orally administered guanylate cyclase type-C receptor agonist for treatment of IBS-C and chronic constipation, was submitted to the US Food and Drug Administration (FDA) with a target action date of June 2012.
|
December 19, 2011
By:From staff reports
The Centers for Medicare & Medicaid Services announced a proposed rule that will increase public awareness of financial relationships between drug and device manufacturers and certain healthcare providers.
|
December 1, 2011
Throughout 2011, Formulary's "Focus on" articles have examined 10 newly approved or investigational drugs of interest to pharmacy and therapeutics (P&T) committee members. Because many readers have said they frequently refer to this column when making formulary decisions for hospitals, health systems, or managed care organizations, the editors have compiled this review of these agents, along with updates on the regulatory status of each.
|
December 1, 2011
By:Jennifer N. Clements, PharmD, BCPS, CDE
The etiology of rheumatoid arthritis is not fully understood, but environmental and genetic factors have been proposed as potential theories. Genetic predisposition results in the destructive nature of this autoimmune disease. The inheritance of certain genes in the major histocompatibility complex can increase the susceptibility of developing RA.
|
November 1, 2011
By:Kejal Patel, PharmD, MBA, Sam Abdelghany, PharmD, BCOP
Crizotinib is a new kinase inhibitor recently approved by FDA for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who express the anaplastic lymphoma kinase gene.
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.